Drug companies' cancer pipelines are bulging, and hundreds of new drugs are in development-the modern equivalent of a gold rush. Remarkable successes have been recorded with targeted oncology, but the treatment of more than 200 types of cancer remains a daunting task. Today' s three principal modalities of cancer treatment-surgery, radiotherapy, drug treatment-have begun to give way to new targeted techniques. Genentech/Roche/Chugai' s Herceptin and ten other blockbuster “targeted” therapies have shown that drugs designed to interact with specifi c molecular targets can hit cancer where it hurts. However, targeted therapies are no panacea; to continue advancing cancer treatment, investigators must continue to improve their understanding of specifi c drug targets and continue to explore gene regulation and protein networks, to which targeted oncology therapies owe their existence.

Get the Answers You Need to Shape Your Strategy

In 2007, there were 11 highly successful targeted cancer blockbusters. Which drugs were they, and which blockbusters also carried a strong warning label: namely, the dreaded “black box” authorized by the FDA?
Amgen recently suffered several setbacks, including unfavorable trial results from a Phase III trial of Vectibix in fi rst-line, metastatic colorectal cancer. But Amgen still has upward of 60 ongoing development programs. Why is this company still in need of a more vibrant pipeline?
Bristol-Myers Squibb has a solid presence in targeted oncology drugs with its blockbuster drug Erbitux. Which other drug in Bristol-Myers Squibb' s portfolio represents a signifi cant achievement in the rational design of drugs to overcome drug resistance in cancer?
With Avastin, Herceptin, and Rituxan/MabThera, Genentech and Roche are on track to rack up more than $11 billion in combined worldwide revenues in 2007. Competition is on the way, however. Which companies have drugs in Phase III trials for non-small-cell lung cancer? What are Genentech/Roche' s strategies for expanding their prolifi c oncology franchise?
For the last few years, ImClone has been sidetracked by legal issues; yet ImClone still claims a legitimate cancer blockbuster: Erbitux, the fi rst targeted cancer therapy approved for colorectal cancer. Why have unfavorable results of Amgen' s Vectibix made clinicians, investigators, and investors anxious about Erbitux' s future potential?
Much excitement accompanied the completion of sequencing the human genome, circa 2000. But the excitement soon gave rise to somber refl ection: the sequencing itself did not immediately point the way to a bevy of new oncology drugs. What work still needs to be done for human genome sequencing to realize its promise of helping to provide personalized, targeted cancer therapies? Scope

Scope

Cancer therapy today and tomorrow: limitations of the three principal modalities of current cancer treatment; addressing unmet needs; targeted cancer therapy and personalized medicine; changes in the drug development paradigm.
Leaders in oncology: the world' s best-selling oncology drugs and the key products in 11 leading oncology franchises.
Oncology pipelines: Amgen' s woes; AstraZeneca' s disappointment; Bristol-Myers Squibb' s expansion; Exelixis' s aggressive discoveries; Genentech/Roche' s leading oncology franchise; Genmab' s waves; GlaxoSmithKline' s oncological advances; ImClone' s legitimate blockbuster; ImmunoGen' s “armed” technology; Novartis' s kinase inhibitors; Pfi zer' s bandwagon-jumping.
Waves of the future: human genome sequencing; the oncology gold rush; RNA targeted therapies.
Spectrum expert commentaries: two separate commentaries in which leading oncology experts

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Cancer Therapy Today and Tomorrow
Targeted Therapy-Hitting Cancer Where it Hurts
Leaders in Oncology
Today' s Reality-Diffi culties in Developing Targeted Therapies
- Toxicities and Black Box Warnings
- Personalized Medicine
  - Murphy' s Law in Effect
  - Key Products in Development
- AstraZeneca' s Initial Disappointment Gives Rise to Changes
- Bristol-Myers Squibb Expands into Biologics
- Exelixis Engages in Aggressive Drug Discovery and Development
  - Third-Party Clinical Financing Vehicle
  - Small-Molecule Kinase Inhibitors
- Genentech/Roche Lead the Way with Oncology Biologics
- Genmab Makes Waves with Largest European Product Deal Ever
- GlaxoSmithKline Advances into Herceptin' s Space in Breast Cancer
- ImClone Faces Ongoing Strife but Boasts a Legitimate Blockbuster
- ImmunoGen Innovates with Armed Antibody Technology
- Novartis Banks on Small-Molecule Kinase Inhibitors
- Pfi zer Moves Beyond Historical Reliance on Small-Molecule Drug Technologies
Waves of the Future
- Somber Refl ection on Human Genome Sequencing
- Mainstay Cancer Treatment Circa 2015
- Personalized Targeted Therapies
- Tomorrow' s RNA Targeted Therapies

Spectrum Expert Commentaries:

“Targeted Oncology Therapy: Trend Toward Personalized Treatment,” by David Z. Chang, M.D., Ph.D., Gastrointestinal Medical Oncology & Immunology, The University of Texas, M.D. Anderson Cancer Center
“The Potential of MicroRNA Modulators as Targeted Oncology Therapies,” by Fabricio F. Costa, Ph.D., Cancer Biology and Epigenomics Program, Children' s Memorial Research Center, Northwestern University' s Feinberg School of Medicine, and Thomas Wurdinger, Ph.D., Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School

Tables:

1. Amgen' s Targeted Oncology Pipeline-Select Products, 2007
2. AstraZeneca' s Targeted Oncology Pipeline-Select Products, 2007
3. Bristol-Myers Squibb' s Targeted Oncology Pipeline-Select Products, 2007
4. Exelixis' s Targeted Oncology Pipeline-Select Products, 2007
5. Genentech and Roche' s Combined Targeted Oncology Pipeline-Select Products, 2007
6. Genmab' s Targeted Oncology Pipeline-Select Products, 2007
7. GlaxoSmithKline' s Targeted Oncology Pipeline-Select Products, 2007
8. ImClone' s Targeted Oncology Pipeline-Select Products, 2007
9. ImmunoGen' s Targeted Oncology Pipeline-Select Products, 2007
10. Novartis' s Targeted Oncology Pipeline-Select Products, 2007
11. Pfi zer' s Targeted Oncology Pipeline-Select Products, 2007